Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial-Reference-Cited by-同舟云学术

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Published:2014-10 Issue:11 Volume:15 Page:1224-1235
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wilke Hansjochen,Muro Kei,Van Cutsem Eric,Oh Sang-Cheul,Bodoky György,Shimada Yasuhiro,Hironaka Shuichi,Sugimoto Naotoshi,Lipatov Oleg,Kim Tae-You,Cunningham David,Rougier Philippe,Komatsu Yoshito,Ajani Jaffer,Emig Michael,Carlesi Roberto,Ferry David,Chandrawansa Kumari,Schwartz Jonathan D,Ohtsu Atsushi

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11;Ferlay,2013

2. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data;Wagner;J Clin Oncol,2006

3. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone;Kang;J Clin Oncol,2012

4. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial;Ford;Lancet Oncol,2014

5. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO);Thuss-Patience;Eur J Cancer,2011

Cited by 1985 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

2. Measurement of changes in serum-based inflammatory indicators to monitor response to nivolumab monotherapy in advanced gastric cancer: a multicenter retrospective study;BMC Cancer;2024-09-09

3. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

4. Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer;Biomedicine & Pharmacotherapy;2024-09

5. United Kingdom and Ireland Oesophagogastric Cancer Group Cancer Update 2023;Clinical Oncology;2024-09